Ranjana Hira Advani MD

Hematologic Oncology

Professor, Medicine - Oncology, Stanford University Medical Center

300 Pasteur DrStanford, CA 94305
Phone+1 650-723-4000

Dr. Advani is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Advani's full profile Already have an account?

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1994 - 1998
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 1987 - 1991
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1989 - 1990
Grant Medical CollegeClass of 1983

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 1988 - 2027
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Rituximab in Treating Patients With Hodgkin's Lymphoma
COMPLETED
PHASE2
Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma Start of enrollment: 2006 Jan 24
TERMINATED
PHASE2
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
COMPLETED
PHASE2

Publications & Presentations

PubMed

Five-year results of short-course brentuximab vedotin combined with chemotherapy and radiation in early stage, unfavorable Hodgkin lymphoma.
Robert Stuver, Esther Drill, Laure Michaud, Carla Casulo, Ranjana H Advani
Haematologica. 2026-10-01
1 citations
B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.
Andrew D Zelenetz, Leo I Gordon, Jeremy S Abramson, Ranjana H Advani, Alaa Altahan
Journal of the National Comprehensive Cancer Network. 2026-09-01
Executive Summary of the American Radium Society Appropriate Use Criteria for Extranodal Natural Killer/T-cell Lymphoma.
Savita V Dandapani, Sairah Ahmed, Timothy Robinson, Ranjana Advani, James Bates
International Journal of Radiation Oncology, Biology, Physics. 2026-09-01

Journal Articles

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Mark P Chao, Sonali M Smith, Ranjana Advani, Ian Flinn, Ravindra Majeti, Nancy L Bartlett, Leslie Popplewell, Justin Kline, Nilanjan Ghosh, Ann LaCasce, The New England Journal of Medicine

Abstracts/Posters

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Co...
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Response to A+CHP by CD30 expression in the ECHELON-2 trial.
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
Emerging Paradigms to Address Unmet Needs in Relapsed/Refractory DLBCL
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Hodgkin Lymphoma: Beyond ABVD for Everyone
60th American Society of Hematology Annual Meeting - 12/1/2018

Press Mentions

Saul Rosenberg, Pioneer in Treating Hodgkin Lymphoma, Dies at 95September 27th, 2022
Non-Chemo Regimen Highly Active in R/R Hodgkin LymphomaAugust 23rd, 2021
International Prognostic Tool Predicts Outcomes in Angioimmunoblastic T-cell LymphomaJune 1st, 2021